Tevogen Bio Holdings Inc. TVGN 深 滬

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

04-27 15:50

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares moved upwards by 145.6%...

04-24 20:05

Tevogen Bio Faces Nasdaq Market Value Compliance Challenges

An update from Tevogen Bio Holdings ( ($TVGN) ) is now available. On April 16, ...

04-23 06:12

Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rare Diseases, And Medical Devices

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries,

03-27 00:56

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen is in advanced-stage evaluation of a niche contract research organization (CRO) that operates across 20+ countries, with a focus on oncology, rare diseases, and medical devices. The potential transaction is expected to add over $20 million in annual revenue, support double-digit growth, and strengthen Tevogen's position in specialized therapeutic areas. CEO Dr. Ryan Saadi expressed optimism about achieving closer to $100 million in annual...

03-26 16:45

Tevogen Bio Regains Nasdaq Compliance

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum

03-26 02:23

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, following a notification on September 23, 2025, that its stock had fallen below the threshold for 30 consecutive days. The company is now advancing its strategy to become a diversified healthcare enterprise, focusing on immunotherapy, artificial intelligence, and efficient capital use. Tevogen is exploring acquisitions and strategic initiatives, includ...

03-25 18:20

Tevogen Reports Advanced Performance For Its AI Platform; Recent Testing Of PredicTcell Model Shows Recall Enhancement From 87% To 92%, Improved Precision From 40% To 48%

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.Tevogen.AI was built to solve a critical

03-14 00:32

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen.AI has enhanced its PredicTcell™ model, improving prediction accuracy to 92% and precision to 48%, with a 20x increase in robustness. The company expanded its peptide database to over 655 million sequences, leveraging AI to accelerate drug discovery, reduce costs, and improve clinical success rates. Tevogen plans to partner with pharma companies to advance peptide candidates and further innovate in immunotherapy.

03-13 16:30

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Tevogen has appointed interim leaders for its core business verticals to advance its diversified growth strategy, with potential annual revenues exceeding $50 million. Leaders in Digital Health, Generics, Contract Research, Biotech, and Artificial Intelligence have been designated. The company expects to finalize transactions by Q2 2026. Tevogen focuses on affordable, efficient healthcare solutions through AI, precision T cell therapy, and collab...

03-09 11:45